4
56 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 2
Bazzaro et al.
and Ub-FL plasmids. M.K.R.M. is indebted to Department
of Science and Technology, New Delhi, India, for their
support (BOYSCAST Fellowship) to carry out this work at
The Johns Hopkins University, Baltimore, MD.
(18) Narisawa-Saito, M.; Kiyono, T. Basic mechanisms of high-risk
human papillomavirus-induced carcinogenesis: roles of E6 and E7
proteins. Cancer Sci. 2007, 98, 1505–1511.
(
19) Boulet, G.; Horvath, C.; Vanden Broeck, D.; Sahebali, S.; Bogers,
J. Human papillomavirus: E6 and E7 oncogenes. Int. J. Biochem.
Cell Biol. 2007, 39, 2006–2011.
(
20) Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S. R.; Huang, P. A
boronic-chalcone derivative exhibits potent anticancer activity
through inhibition of the proteasome. Mol. Pharmacol. 2006, 70,
Supporting Information Available: Synthesis details and ana-
lytical data of intermediates and products 2-10; specificity and
reversibility data. This material is available free of charge via the
Internet at http://pubs.acs.org.
4
26–433.
(
21) Bonfili, L.; Cecarini, V.; Amici, M.; Cuccioloni, M.; Angeletti, M.;
Keller, J. N.; Eleuteri, A. M. Natural polyphenols as proteasome
modulators and their role as anti-cancer compounds. FEBS J.
References
2
008, 275, 5512–5526.
(
1) Ciechanover, A.; Finley, D.; Varshavsky, A. The ubiquitin-
mediated proteolytic pathway and mechanisms of energy-
dependent intracellular protein degradation. J. Cell. Biochem.
(22) Cuccioloni, M.; Mozzicafreddo, M.; Bonfili, L.; Cecarini, V.;
Eleuteri, A. M.; Angeletti, M. Natural occurring polyphenols as
template for drug design. Focus on serine proteases. Chem. Biol.
Drug Des. 2009, 74, 1–15.
(23) Milacic, V.; Banerjee, S.; Landis-Piwowar, K. R.; Sarkar, F. H.;
Majumdar, A. P.; Dou, Q. P. Curcumin inhibits the proteasome
activity in human colon cancer cells in vitro and in vivo. Cancer
Res. 2008, 68, 7283–7292.
1
2) Ciechanover, A. The ubiquitin-mediated proteolytic pathway.
984, 24, 27–53.
(
(
Brain Pathol. 1993, 3, 67–75.
3) Orlowski, M.; Wilk, S. Catalytic activities of the 20 S proteasome, a
multicatalytic proteinase complex. Arch. Biochem. Biophys. 2000,
3
83, 1–16.
(24) Mozzicafreddo, M.; Cuccioloni, M.; Bonfili, L.; Eleuteri, A. M.;
Fioretti, E.; Angeletti, M. Antiplasmin activity of natural occurring
polyphenols. Biochim. Biophys. Acta 2008, 1784, 995–1001.
(25) Bogyo, M.; Shin, S.; McMaster, J. S.; Ploegh, H. L. Substrate
binding and sequence preference of the proteasome revealed by
active-site-directed affinity probes. Chem. Biol. 1998, 5, 307–320.
(26) Kessler, B. M.; Tortorella, D.; Altun, M.; Kisselev, A. F.; Fiebiger,
E.; Hekking, B. G.; Ploegh, H. L.; Overkleeft, H. S. Extended
peptide-based inhibitors efficiently target the proteasome and
reveal overlapping specificities of the catalytic beta-subunits.
Chem. Biol. 2001, 8, 913–929.
(
4) Bazzaro, M.; Lin, Z.; Santillan, A.; Lee, M. K.; Wang, M. C.;
Chan, K. C.; Bristow, R. E.; Mazitschek, R.; Bradner, J.; Roden,
R. B. Ubiquitin proteasome system stress underlies synergistic
killing of ovarian cancer cells by bortezomib and a novel HDAC6
inhibitor. Clin. Cancer Res. 2008, 14, 7340–7347.
5) Bazzaro, M.; Lee, M. K.; Zoso, A.; Stirling, W. L.; Santillan, A.;
Shih Ie, M.; Roden, R. B. Ubiquitin-proteasome system stress
sensitizes ovarian cancer to proteasome inhibitor-induced apopto-
sis. Cancer Res. 2006, 66, 3754–3763.
6) Curran, M. P.; McKeage, K. Bortezomib: a review of its use in
patients with multiple myeloma. Drugs 2009, 69, 859–888.
7) Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd,
G. K.; Potts, B. C. Discovery and development of the anticancer
agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009,
(
(
(27) Marastoni, M.; Baldisserotto, A.; Trapella, C.; Gavioli, R.;
Tomatis, R. Synthesis and biological evaluation of new vinyl ester
pseudotripeptide proteasome inhibitors. Eur. J. Med. Chem. 2006,
41, 978–984.
(
1
7, 2175–2180.
(28) Baldisserotto, A.; Marastoni, M.; Fiorini, S.; Pretto, L.; Ferretti, V.;
Gavioli, R.; Tomatis, R. Vinyl ester-based cyclic peptide proteasome
inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 1849–1854.
(29) Chauhan, D.; Hideshima, T.; Anderson, K. C. Targeting protea-
somes as therapy in multiple myeloma. Adv. Exp. Med. Biol. 2008,
615, 251–260.
(30) Baldisserotto, A.; Destro, F.; Vertuani, G.; Marastoni, M.;
Gavioli, R.; Tomatis, R. N-terminal-prolonged vinyl ester-based
peptides as selective proteasome beta1 subunit inhibitors. Bioorg.
Med. Chem. 2009, 17, 5535–5540.
(
8) Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk,
K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; van Leeuwen,
F. W.; Chanan-Khan, A. A.; Orlowski, R. Z. Potent activity
of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-
proteasome pathway, against preclinical models of multiple myeloma.
Blood 2007, 110, 3281–3290.
9) Genin, E.; Reboud-Ravaux, M.; Vidal, J. Proteasome inhibitors:
recent advances and new perspectives in medicinal chemistry. Curr.
Top. Med. Chem. 2010, 10, 232–256.
(
(
10) Basse, N.; Montes, M.; Marechal, X.; Qin, L.; Bouvier-Durand,
M.; Genin, E.; Vidal, J.; Villoutreix, B. O.; Reboud-Ravaux, M.
Novel organic proteasome inhibitors identified by virtual and in
vitro screening. J. Med. Chem. 2010, 53, 509–513.
(31) Luker, G. D.; Pica, C. M.; Song, J.; Luker, K. E.; Piwnica-Worms,
D. Imaging 26S proteasome activity and inhibition in living mice.
Nat. Med. 2003, 9, 969–973.
(32) Groll, M.; Huber, R. Purification, crystallization, and X-ray
analysis of the yeast 20S proteasome. Methods Enzymol. 2005,
398, 329–336.
(33) McElvain, S. M.; McMahon, R. E. Piperidine derivatives. 4-piper-
idone, 4-piperidinol and certain of their derivatives. J. Am. Chem.
Soc. 1949, 71, 3.
(
11) Kaiser, M.; Groll, M.; Renner, C.; Huber, R.; Moroder, L. The
core structure of TMC-95A is a promising lead for reversible
proteasome inhibition. Angew. Chem., Int. Ed. 2002, 41, 780–783.
12) Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.;
Shimizu, R.; Ohnuki, T.; Komatsubara, S. Structures of TMC-
(
9
5A-D: novel proteasome inhibitors from Apiospora montagnei
(34) Gavioli, R.; Vertuani, S.; Masucci, M. G. Proteasome inhibitors
reconstitute the presentation of cytotoxic T-cell epitopes in Ep-
stein-Barr virus-associated tumors. Int. J. Cancer 2002, 101, 532–538.
(35) Hendil, K. B.; Uerkvitz, W. The human multicatalytic proteinase:
affinity purification using a monoclonal antibody. J. Biochem.
Biophys. Methods 1991, 22, 159–165.
sacc. TC 1093. J. Org. Chem. 2000, 65, 990–995.
(
(
13) Laurent, N.; de Bouard, S.; Guillamo, J. S.; Christov, C.; Zini, R.;
Jouault, H.; Andre, P.; Lotteau, V.; Peschanski, M. Effects of the
proteasome inhibitor ritonavir on glioma growth in vitro and in
vivo. Mol. Cancer Ther. 2004, 3, 129–136.
14) Basse, N.; Papapostolou, D.; Pagano, M.; Reboud-Ravaux, M.;
Bernard, E.; Felten, A. S.; Vanderesse, R. Development of lipopep-
tides for inhibiting 20S proteasomes. Bioorg. Med. Chem. Lett.
(36) Belley, B. Massive thermostatins in isothermal density functional
molecular dynamics simulations. J. Chem. Phys. 1990, 50, 1.
(37) Groll, M.; Larionov, O. V.; Huber, R.; de Meijere, A. Inhibitor-
binding mode of homobelactosin C to proteasomes: new insights
into class I MHC ligand generation. Proc. Natl. Acad. Sci. U.S.A.
2006, 103, 4576–4579.
(38) Groll, M.; Balskus, E. P.; Jacobsen, E. N. Structural analysis of
spiro beta-lactone proteasome inhibitors. J. Am. Chem. Soc. 2008,
130, 14981–1483.
2006, 16, 3277–3281.
(
(
(
15) Dick, L. R.; Fleming, P. E. Building on bortezomib: second-
generation proteasome inhibitors as anti-cancer therapy. Drug
Discovery Today 2010, 15, 243–249.
16) Hawley-Nelson, P.; Vousden, K. H.; Hubbert, N. L.; Lowy, D. R.;
Schiller, J. T. HPV16 E6 and E7 proteins cooperate to immortalize
human foreskin keratinocytes. EMBO J. 1989, 8, 3905–3910.
17) Reinstein, E.; Scheffner, M.; Oren, M.; Ciechanover, A.; Schwartz,
A. Degradation of the E7 human papillomavirus oncoprotein by
the ubiquitin-proteasome system: targeting via ubiquitination of
the N-terminal residue. Oncogene 2000, 19, 5944–5950.
(39) Ponder, J. W.; Case, D. A. Force fields for protein simulations.
Adv. Protein Chem. 2003, 66, 27–85.
(40) Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect
relashionship: the combined effects of multiple drugs or enzyme
inhibitors. Adv. Enzyme Regul. 1984, 22, 27–55.